Literature DB >> 25220832

Bone turnover markers in serum and urine as diagnostic, prognostic and monitoring biomarkers of bone metastasis.

Klaus Jung1, Michael Lein2.   

Abstract

Bone metastases are characterized by increased osteoblastic and/or osteolytic processes depending on the tumor type. The altogether destructive effect of metastasis formation promoted by increased metabolic activity raises the release of components from the osseous metabolism into the blood stream. These components are either enzymes directly involved in the alteration processes, metabolites/proteins that develop during this or bone matrix proteins released during this. These biomarkers are categorized in relation to their involvement in the bone formation or resorption as bone formation and resorption markers. Based on a PubMed literature search, a critical appraisal of the various biomarkers for diagnostic, prognostic, and monitoring purposes is given for patients with skeletal metastases caused by breast, prostate, lung, or renal cell carcinomas.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bone markers; Cancer; Diagnostic biomarker; Osseous metastasis; Prognostic biomarker

Mesh:

Substances:

Year:  2014        PMID: 25220832     DOI: 10.1016/j.bbcan.2014.09.001

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  23 in total

Review 1.  Bone remodeling markers and bone metastases: From cancer research to clinical implications.

Authors:  Arlindo Ferreira; Irina Alho; Sandra Casimiro; Luís Costa
Journal:  Bonekey Rep       Date:  2015-04-22

Review 2.  Metastatic tumors to the jaws and mouth.

Authors:  Abraham Hirshberg; Raanan Berger; Irit Allon; Ilana Kaplan
Journal:  Head Neck Pathol       Date:  2014-11-20

Review 3.  Detection of inflammatory biomarkers in saliva and urine: Potential in diagnosis, prevention, and treatment for chronic diseases.

Authors:  Sahdeo Prasad; Amit K Tyagi; Bharat B Aggarwal
Journal:  Exp Biol Med (Maywood)       Date:  2016-03-24

4.  Bone remodeling and regulating biomarkers in women at the time of breast cancer diagnosis.

Authors:  Song Yao; Yali Zhang; Li Tang; Janise M Roh; Cecile A Laurent; Chi-Chen Hong; Theresa Hahn; Joan C Lo; Christine B Ambrosone; Lawrence H Kushi; Marilyn L Kwan
Journal:  Breast Cancer Res Treat       Date:  2016-12-03       Impact factor: 4.872

5.  Deep Learning for the Automatic Diagnosis and Analysis of Bone Metastasis on Bone Scintigrams.

Authors:  Simin Liu; Ming Feng; Tingting Qiao; Haidong Cai; Kele Xu; Xiaqing Yu; Wen Jiang; Zhongwei Lv; Yin Wang; Dan Li
Journal:  Cancer Manag Res       Date:  2022-01-03       Impact factor: 3.989

6.  Risk factor analysis of bone metastasis in patients with non-small cell lung cancer.

Authors:  Yang Li; Chongqing Xu; Qiquan Yu
Journal:  Am J Transl Res       Date:  2022-09-15       Impact factor: 3.940

Review 7.  The best of both worlds - managing the cancer, saving the bone.

Authors:  Issam Makhoul; Corey O Montgomery; Dana Gaddy; Larry J Suva
Journal:  Nat Rev Endocrinol       Date:  2015-10-27       Impact factor: 43.330

8.  Advanced Oxidation Protein Products as a Novel Marker of Oxidative Stress in Postmenopausal Osteoporosis.

Authors:  Qian Wu; Zhao-Ming Zhong; Ying Pan; Ji-Huan Zeng; Shuai Zheng; Si-Yuan Zhu; Jian-Ting Chen
Journal:  Med Sci Monit       Date:  2015-08-18

9.  SOST Inhibits Prostate Cancer Invasion.

Authors:  Bryan D Hudson; Nicholas R Hum; Cynthia B Thomas; Ayano Kohlgruber; Aimy Sebastian; Nicole M Collette; Matthew A Coleman; Blaine A Christiansen; Gabriela G Loots
Journal:  PLoS One       Date:  2015-11-06       Impact factor: 3.240

10.  Hypercalcemia of malignancy treated with cinacalcet.

Authors:  Nikolaos Asonitis; Eva Kassi; Michalis Kokkinos; Ilias Giovanopoulos; Foteini Petychaki; Helen Gogas
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2017-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.